Stock Track | Ginkgo Bioworks Soars 5.02% as Partner Lucid Diagnostics' Esophageal DNA Test Accepted for Publication

Stock Track2024-12-11

Ginkgo Bioworks Holdings Inc. (DNA) stock soared 5.02% on Wednesday, likely boosted by positive news regarding its partner company Lucid Diagnostics.

Lucid Diagnostics, a commercial-stage cancer prevention medical diagnostics company, announced that its prospective clinical utility study for the EsoGuard® Esophageal DNA Test has been accepted for publication in the peer-reviewed journal Medicina.

The EsoGuard test is designed to detect esophageal precancer and cancer through early detection in at-risk patients. The clinical study demonstrated outstanding clinical utility, including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard testing in a real-world clinical setting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment